4B CEDAR BROOK DRIVE, CRANBURY, NJ
Amended material disclosure
Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option
Announces Pricing of Upsized $15.8 Million Public Offering
Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration
Other Events
To develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws, Reg. FD
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
S-1
Direct Registration System
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence